ALK and non-small cell lung carcinoma: Alectinib was approved by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) as a first-line treatment for patients with ALK mutations with metastatic NSCLC and for those who progress on crizotinib as a first line treatment, based on the data from the phase 3 ALEX trial [8,9,10].